Magnetic Resonance Imaging Development for High Resolution Atrial Structural and Functional Characterization
NCT ID: NCT06617624
Last Updated: 2024-09-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
120 participants
OBSERVATIONAL
2024-09-30
2026-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Left atrial cine: compressed sensing cine imaging strategies will be tested for LA assessment by optimizing spatial and temporal resolution providing the best image quality relative to acceptable acquisition times. The whole heart should be covered during acquisition. Image quality and diagnosis of LA contraction preservation will be performed.
2. Myocardial tissue characterization including:
1. 3D isotropic ECG-gated with respiratory navigation late gadolinium enhancement (LGE) sequence for high resolution imaging of myocardial injury and fibrosis.
2. High resolution free-breathing T1/T2 mapping to quantify myocardial water content and measure native T1 relaxation and extracellular volume. 2D free breathing LGE will complement the protocol.
3. Cardiac adipose tissue imaging will be performed using gated Dixon imaging. Pericardial adipose tissue (PAT) will be measured covering the whole heart including groove epicardial adipose tissue (EAT).
3. Flow measurements: test and optimize a 4D flow approach for the heart and aorta using compressed sensing and multi velocity encoding (VENC) encoding to insure high and precise multi-chamber velocity imaging(100, 150, 200, 250 cm/s). Two-chamber (including left appendage) in plane velocities will be compared between high resolution 2D and 4D. Of, note, such multi-VENC approach is mandatory for LA imaging because of the large heterogeneity of blood flow velocities within the LA during the cardiac cycle.
4. Technology validation: comparison of cardiac triggering using the beat sensor vs. surface ECG-gating will be tested as a means of improving patient experience and speed up MRI acquisition for subsequent population imaging.
This task will be performed at the Cardiovascular MRI Imaging Platform and Core Lab at the Pitié-Salpêtrière Hospital site by SU-ICAN \& APHP (ICT), SU-LIB and SIEMENS partners with the goal to optimize, test and validate innovative approaches before wider application.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1: patient with paroxysmal AF (Atrial Fibrillation) (no AF during exam)
20 patients able to complete the full standard experimental examination corresponding to paroxysmal AF group
MRI Contrast
Patients will have the gadolinium injected cardiovascular MRI
Group 2: patient with persistent AF (Atrial Fibrillation)
20 patients able to complete the full standard experimental examination corresponding to persistent AF group
MRI Contrast
Patients will have the gadolinium injected cardiovascular MRI
Group 3: patient with permanent AF (Atrial Fibrillation)
20 patients able to complete the full standard experimental examination corresponding to permanent AF group
MRI Contrast
Patients will have the gadolinium injected cardiovascular MRI
Group 4: healthy volunteer
60 age/sex BMI class matched healthy volunteers, able to complete the full standard experimental examination.
MRI
Healthy volunteer will have a non-injected cardiovascular MRI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRI
Healthy volunteer will have a non-injected cardiovascular MRI
MRI Contrast
Patients will have the gadolinium injected cardiovascular MRI
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Over 18 years of age
* Participation to the MAESTRIA-AFNET 10 study
* Able to undergo an injected MRI examination
* Able to give consent
* Affiliated to French social security system
For healthy volunteers (Group 4):
* Over 18 years of age (including 30 subjects \< 60 years)
* Able to undergo an MRI examination
* Able to give consent
* Affiliated to French social security system
Exclusion Criteria
* Deprived of liberty or under legal protection (under guardianship or curatorship)
* Kidney disease with GFR \<30 mL / min (because of the risks linked to the injection of DOTAREM ™ and iodine)
* Pregnant woman, breastfeeding, of childbearing age in the absence of effective contraception
* MRI contraindication (claustrophobia, patients with metallic foreign bodies)
* Participation to another interventional clinical trial (Jardé 1) For patients
* Patients with a history of renal disease (renal transplant, single kidney, renal cancer)
* Patients who have received a dose of contrast in the last 24 hours
* Patients who had a previous allergic or anaphylactic reaction to gadolinium For volunteers
* Subjects with known cardiovascular pathology or under cardiovascular treatment
* Subjects with cardiovascular history
* Subjects with cardiac rhythm or conduction disorders
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-A01951-44
Identifier Type: OTHER
Identifier Source: secondary_id
APHP231076
Identifier Type: -
Identifier Source: org_study_id